Nothing Special   »   [go: up one dir, main page]

HK1117172A1 - P-cadherin antibodies - Google Patents

P-cadherin antibodies

Info

Publication number
HK1117172A1
HK1117172A1 HK08107649.2A HK08107649A HK1117172A1 HK 1117172 A1 HK1117172 A1 HK 1117172A1 HK 08107649 A HK08107649 A HK 08107649A HK 1117172 A1 HK1117172 A1 HK 1117172A1
Authority
HK
Hong Kong
Prior art keywords
antibody
cadherin
seq
antibodies
antigen
Prior art date
Application number
HK08107649.2A
Other languages
English (en)
Chinese (zh)
Other versions
HK1117172B (en
Inventor
克里斯托弗.托德.保尔
莫琳.杰瑞.鲍内
孟拉尼.波耶勒
杰拉尔德.菲尔斯.加斯波森
大卫.威廉.格里格斯
理查德.大卫.汉德
威廉.迪恩.卓恩
理查德.艾伦.玛扎艾勒
拉尔夫.雷蒙德.米特尔
马克.艾伦.莫法特
巴雷特.理查德.思伊拉
托德.李.瓦纳斯达勒
Original Assignee
辉瑞有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 辉瑞有限公司 filed Critical 辉瑞有限公司
Publication of HK1117172A1 publication Critical patent/HK1117172A1/xx
Publication of HK1117172B publication Critical patent/HK1117172B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK08107649.2A 2005-04-26 2006-04-13 P-cadherin antibodies HK1117172B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67531105P 2005-04-26 2005-04-26
US60/675,311 2005-04-26
PCT/IB2006/001053 WO2006114704A2 (fr) 2005-04-26 2006-04-13 Anticorps de la p-cadherine

Publications (2)

Publication Number Publication Date
HK1117172A1 true HK1117172A1 (en) 2009-01-09
HK1117172B HK1117172B (en) 2012-11-23

Family

ID=

Also Published As

Publication number Publication date
DOP2006000098A (es) 2006-10-31
AR085624A2 (es) 2013-10-16
MY146773A (en) 2012-09-28
US7928214B2 (en) 2011-04-19
AR053456A1 (es) 2007-05-09
CN101184778A (zh) 2008-05-21
TW200718712A (en) 2007-05-16
EP2444419A1 (fr) 2012-04-25
JP4253037B2 (ja) 2009-04-08
CA2604357C (fr) 2012-01-17
WO2006114704A3 (fr) 2007-03-22
PH12014501872A1 (en) 2016-08-31
US7452537B2 (en) 2008-11-18
IL186413A (en) 2016-09-29
JP2008538909A (ja) 2008-11-13
TW201035110A (en) 2010-10-01
KR100990027B1 (ko) 2010-10-26
US20060240001A1 (en) 2006-10-26
TWI379838B (en) 2012-12-21
TNSN07398A1 (fr) 2009-03-17
AP2007004191A0 (en) 2007-10-31
GT200600176A (es) 2006-11-28
KR20110113785A (ko) 2011-10-18
AP2552A (en) 2013-01-08
ZA200708548B (en) 2008-11-26
BRPI0608096A2 (pt) 2009-11-10
NO20074916L (no) 2007-10-25
JP5086974B2 (ja) 2012-11-28
CU23764A3 (es) 2012-02-15
US20110182884A1 (en) 2011-07-28
KR101203328B1 (ko) 2012-11-20
EP2444421A1 (fr) 2012-04-25
CN101184778B (zh) 2012-05-30
MX2007013304A (es) 2007-12-13
US8974781B2 (en) 2015-03-10
KR20100038467A (ko) 2010-04-14
IL234657A0 (en) 2014-11-30
EP2444420A1 (fr) 2012-04-25
UY37223A (es) 2018-11-30
HN2006015949A (es) 2011-01-17
CA2763671A1 (fr) 2006-11-02
PE20061376A1 (es) 2006-12-19
US20090118487A1 (en) 2009-05-07
NO20181306A1 (no) 2007-10-25
UA95775C2 (uk) 2011-09-12
AU2006238930A1 (en) 2006-11-02
CA2604357A1 (fr) 2006-11-02
IL186413A0 (en) 2008-01-20
KR101193797B1 (ko) 2012-10-23
EA200702087A1 (ru) 2008-02-28
AU2006238930B2 (en) 2010-12-23
JP2009106287A (ja) 2009-05-21
WO2006114704A2 (fr) 2006-11-02
NZ562234A (en) 2009-09-25
CR9471A (es) 2007-12-04
KR20070116155A (ko) 2007-12-06
GEP20115226B (en) 2011-06-10
EA012970B1 (ru) 2010-02-26
MA29991B1 (fr) 2008-12-01
EP1877444A2 (fr) 2008-01-16

Similar Documents

Publication Publication Date Title
JP4253037B2 (ja) P−カドヘリン抗体
KR101536487B1 (ko) 액티빈 수용체 유사 키나제-1에 대한 인간 모노클로날 항체
NL1031818C2 (nl) P-Cadherineantilichamen.
HK1117172B (en) P-cadherin antibodies
CA2763805A1 (fr) Anticorps de la p-cadherine
HK1131632A (en) Human monoclonal antibodies to activin receptor-like kinase-1

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200413